On June 23, WuXi XDC rose 3.24% in regular trading, trading at 49.38 HKD/share, with turnover of approximately HKD 106 million. The stock has posted gains for multiple consecutive sessions driven by a combination of broker endorsement and subsidiary business developments.

On the news front, BOCOM International recently issued a research report highlighting WuXi XDC as a top recommendation among leading players in high-growth biotech service tracks, citing strong investment value. Additionally, the company's controlled subsidiary Topharma signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharma will provide process development and manufacturing services for 10 batches of monoclonal antibody intermediates at RMB 1.9 million per batch, totaling RMB 19 million. The agreement is expected to help Topharma deepen its technical know-how, enhance process capabilities, and support future business expansion.

Within the Life Sciences Tools & Services sector, peers also traded higher, with Insilico up 6.05%, XtalPi up 3.71%, GenScript Biotech up 2.72%, WuXi Biologics up 2.28%, and WuXi AppTec up 0.9%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)